Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort

Cancer

Volumn 119, Issue 13, 2013, Pages 2375-2382

  Castel, Liana D ^a   Hartmann, Katherine E ^a   Mayer, Ingrid A ^a   Saville, Benjamin R ^b   Alvarez, Joann ^b   Boomershine, Chad S ^a   Abramson, Vandana G ^a   Chakravarthy, A Bapsi ^a   Friedman, Debra L ^a   Cella, David F ^c  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

aromatase inhibitors; arthralgia; breast neoplasms; joint pain; longitudinal studies; postmenopause

Indexed keywords

AROMATASE INHIBITOR; TAMOXIFEN;

ADULT; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; COHORT ANALYSIS; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMPLOYMENT STATUS; FEMALE; HUMAN; ILLNESS TRAJECTORY; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; PAIN ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; ARTHRALGIA; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; POISSON DISTRIBUTION; POSTMENOPAUSE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84879102201     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28016     Document Type: Article

References (37)

1. Buzdar A,. Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial. Clin Breast Cancer. 2003; 4 (suppl 1): S42-S48.
2. American Cancer Society. Cancer Treatment and Survivorship Facts & Figures 2012-2013. Atlanta, GA: American Cancer Society; 2012.
3. Cella D, Fallowfield LJ,. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat. 2008; 107: 167-180.
4. Henry NL, Giles JT, Ang D, et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat. 2008; 111: 365-372.
5. Cella D, Fallowfield L, Barker P, et al. Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat. 2006; 100: 273-284.
6. van Herk-Sukel MP, van de Poll-Franse LV, Voogd AC, et al. Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Res Treat. 2010; 122: 843-851.
7. Henry NL, Azzouz F, Desta Z, et al. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol. 2012; 30: 936-942.
8. Partridge AH, LaFountain A, Mayer E, et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol. 2008; 26: 556-562.
9. Crew KD, Greenlee H, Capodice, J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007; 25: 3877-3883.
10. Moy B, Tu D, Pater JL, et al. Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer. Ann Oncol. 2006; 17: 1637-1643.
11. Sestak I, Cuzick J, Sapunar F, et al. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol. 2008; 9: 866-872.
12. Donnellan PP, Douglas SL, Cameron DA, Leonard RC,. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001; 19: 2767.
13. Presant CA, Bosserman L, Young T, et al. Aromatase inhibitor-associated arthralgia and/ or bone pain: frequency and characterization in non-clinical trial patients. Clin Breast Cancer. 2007; 7: 775-778.
14. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009; 42: 377-381.
15. Cunningham LS, Kelsey JL,. Epidemiology of musculoskeletal impairments and associated disability. Am J Public Health. 1984; 74: 574-579.
16. Basch E, Artz D, Dulko D, et al. Patient online self-reporting of toxicity symptoms during chemotherapy. J Clin Oncol. 2005; 23: 3552-3561.
17. Kroenke K, Spitzer RL, Williams JB,. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003; 41: 1284-1292.
18. Basch E, Iasonos A, Barz A, et al. Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol. 2007; 25: 5374-5380.
19. Fallowfield LJ, Leaity SK, Howell A, Benson S, Cella D,. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat. 1999; 55: 189-199.
20. Rose M, Bjorner JB, Becker J, Fries JF, Ware JE,. Evaluation of a preliminary physical function item bank supported the expected advantages of the Patient-Reported Outcomes Measurement Information System (PROMIS). J Clin Epidemiol. 2008; 61: 17-33.
21. Yu L, Buysse DJ, Germain A, et al. Development of short forms from the PROMIS™ sleep disturbance and sleep-related impairment item banks. Behav Sleep Med. 2011; 10: 6-24.
22. Godin G, Shephard RJ,. A simple method to assess exercise behavior in the community. Can J Appl Sport Sci. 1985; 10: 141-146.
23. Wolfe F,. Pain extent and diagnosis: development and validation of the regional pain scale in 12,799 patients with rheumatic disease. J Rheumatol. 2003; 30: 369-378.
24. Helzlsouer KJ, Gallicchio L, Macdonald R, Wood B, Rushovich E,. A prospective study of aromatase inhibitor therapy, vitamin D, C-reactive protein and musculoskeletal symptoms. Breast Cancer Res Treat. 2012; 131: 277-285.
25. Robidoux A, Rich E, Bureau NJ, et al. A prospective pilot study investigating the musculoskeletal pain in postmenopausal breast cancer patients receiving aromatase inhibitor therapy. Curr Oncol. 2011; 18: 285-294.
26. Zlowodzki M, Bhandari M,. Outcome measures and implications for sample-size calculations. J Bone Joint Surg Am. 2009; 91 (suppl 3): 35-40.
27. Ju YH, Doerge DR, Woodling KA, et al. Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo. Carcinogenesis. 2008; 29: 2162-2168.
28. Prieto-Alhambra D, Javaid MK, Servitja S, et al. Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study. Breast Cancer Res Treat. 2011; 125: 869-878.
29. Prieto-Alhambra D, Javaid MK,. Aromatase inhibitor-induced arthralgia: is vitamin D deficiency responsible? Maturitas. 2011; 69: 3-4.
30. Boonen S, Haentjens P, Vandenput L, Vanderschueren D,. Preventing osteoporotic fractures with antiresorptive therapy: implications of microarchitectural changes. J Intern Med. 2004; 255: 1-12.
31. Burstein HJ,. Aromatase inhibitor-associated arthralgia syndrome. Breast. 2007; 16: 223-234.
32. Thorne C,. Management of arthralgias associated with aromatase inhibitor therapy. Curr Oncol. 2007; 14 (suppl 1): S11-S19.
33. Dent SF, Gaspo R, Kissner M, et al. Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer. Breast Cancer Res Treat. 2011; 126: 295-310.
34. Fallowfield L,. Acceptance of adjuvant therapy and quality of life issues. Breast. 2005; 14: 612-616.
35. Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010; 28: 4120-4128.
36. Pocock SJ, Assmann SE, Enos LE, Kasten LE,. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med. 2002; 21: 2917-2930.
37. Hadji P,. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol. 2010; 73: 156-166.